Study of Sintilimab, a PD-1 Inhibitor, as Second-line Treatment in FH-deficient Renal Cell Carcinoma

Conditions:   Renal Cell Carcinoma;   FH-deficient;   Sintilimab Intervention:   Drug: Sintilimab Sponsor:   West China Hospital Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials